SCD Modulating Compounds for Brain Cancer and Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurological disorders such as Parkinson's Disease and Alzheimer's Disease provide limited relief, and treatments for brain cancers are often ineffective, leading to a need for improved methods and compositions for treating these conditions.
Innovation Solution
Administration of a compound that modulates the activity of SCDs (such as SCD1 and SCD5) or a pharmaceutical composition containing such a compound, which may include specific structures represented by formulas (I), (II), (III), (III-A), (III-B), (III-C), (III-D), (III-D-1), (III-D-2), or (IV), among others, to treat primary brain cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for neurological disorders such as Parkinson's Disease and Alzheimer's Disease, then treatment is provided, but the relief is very limited
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (formulas I-IV) that target SCD enzymes differently from existing therapies. The compounds feature varied substituent groups (R1-R6, L1, L2) and ring structures (X1-X4) that modify their interaction with the target enzyme, thereby changing the therapeutic parameter of disease modification capability while maintaining therapeutic effectiveness
2Reliability
If chemotherapy is used along with surgery and radiation for brain cancer, then treatment is provided, but survival is rarely extended much beyond what surgery and radiation alone produce
Solution Approach 1:
The patent extracts and targets a specific molecular pathway (SCD enzyme activity) that is crucial for brain cancer survival. By developing compounds that specifically inhibit SCD1 and SCD5 enzymes, the treatment isolates and attacks a key vulnerability in cancer cells without requiring complex combination therapies, thereby extending survival with a more focused regimen
3Loss of information
If robust model systems are limited, then research is constrained, but understanding of molecular perturbations causing disease remains incomplete
Solution Approach 1:
The patent uses SCD enzyme inhibitors as intermediary compounds to study and understand molecular perturbations in neurodegenerative diseases and brain cancer. These compounds serve as mediators that allow researchers to probe specific molecular pathways and mechanisms, thereby reducing the loss of information about disease causation even when robust model systems are limited
Data Source
AI summary
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.